Spanish regulators BAN £51 nasal spray that may cut risk from Covid (2024)

Spanish drug regulators have banned the sale of a readily-available nasal spray touted as a potential coronavirus treatment.

The Taffix spray, sold in a pack of four for £51, was credited with preventing dozens of Jews from catching Covid at a religious festival in Israel last year.

But despite its promise, Spain's medical regulator, the Agency for Medicines and Health Products (AEMPS), has banned its sale on the basis there was'not enough clinical evidence' it was effective.

The UK's medicines regulator said it was also reviewing the nasal spray.

Experts say unproven Covid remedies may give people false confidence to be riskier in their behaviour, such as visiting a vulnerable relative.

Taffix's main chemical ingredient hypromellose is often used as an antiseptic before surgery to stop patients from getting infections.

The spray — which claims to block 97 per cent of all airborne viruses — has a vital 'CE mark', meaning it has been deemed safe to use in Europe.

But data on its effectiveness on Covid is still uncertain.

A spokesman for the UK regulator - the Medicines and Healthcare products Regulatory Agency (MHRA) - said: 'We have taken appropriate steps in response to enquiries raised regarding Taffix, and will continue with our review of the situation.

'Patient safety remains front and centre in all our actions. The MHRA publicly communicates patient safety messages when necessary.'

A study by Nasus, the Israeli biomedical firm which makes the spray, and scientists from the University of Haifa and the University of Virginia, followed 243 people who attended aJewish new year festival last September in the city of Bney Brak, four miles (6.3km) east of Tel Aviv.

None of the 81 Jews who used the spray properly got infected, compared to 16 in the other group who did.

The spray — which provides enough for 200 pumps in each bottle —is said to coat the inside of the nose in an acidic powder that makes it difficult for viral particles to penetrate.

Despite not being subject to the same rigour as a controlled scientific study, it provides one of the largest real-world tests of the sprays – which some scientists believe could play an important role in fighting the pandemic.

However, Nasus Pharma warned the nasal spray is not a substitution for face masks or social isolation and should be used as an 'addition'.

Other lab-based studies have shown it can stop the virus from replicating in petri dishes, but there has been little real-world research on its efficacy.

It is not known if the firm is planning on conducting rigorous scientific trials to prove whether their nasal spray works.

Taffix’s spray has no known side effects, according to an FAQ on its website – but may cause a ‘tingling or burning sensation in the nose’.

The spray prevents infection by capturing the virus in the nose and coating it. This means the virus cannot escape and renders the it inactive and harmless.

The researchers believe using the spray four times a day will be enough for general protection.

However, it is safe enough to be applied every 20 minutes if required, for example, if a user is in a high-risk environment.

Other scientists are also developing nasal sprays to fight off Covid, including a team at the University of Birmingham.

Their spray - which has not been named - has been in development since April last year and could hit the shelves as early as this summer.

It is made from ingredients that are already approved for medical use in the UK, meaning it is safe for humans and does not require further clearance.